To define the functional contribution of SMYD3 to colorectal cancer (CRC) progression, we combined genetic loss-of-function, pharmacologic inhibition, and gain-of-function approaches in SW480 and HCT116 cells. This evidence concerns the gene SMYD3 and colorectal carcinoma.